Subsequent GLP1RA trials including LEADER and SUSTAIN-6 had small populations of patients with established HF, therefore limiting any potential generalizations about HF risk with GLP1RA (54,55)
This guide compares the two on mechanism, efficacy, approval status, cost, and side effects, then explains which one fits which situation
(Remember: You should never alter your dosage without first consulting your prescriber.) My tailor had already taken the dress down two to three sizes from what I originally ordered, so I intentionally slowed my progress to make sure everything fit just right, she says
[52] Substitutions are made at GLP positions 8 and 34 (semaglutide positions 2 and 28), where alanine and lysine are replaced by 2-aminoisobutyric acid and arginine, respectively